Replies to post #115799 on Biotech Values

[jbog]

Ciotera

Isn't Tysabri limited to the most severe later line patients as a treatment of "last resort"?

You are correct that Tysabri is for the most severe MS patient, but that can almost happen right from the get go.

[DewDiligence]

My guess would be that [Gilenya] would steal most patients from Avonex.

You don’t have to guess—NVS has provided the hard data in #msg-59293907. Regards, Dew